US prescription volumes were constant over the same period, in line with the mesalamine / olsalazine market growth.
PENTASA had an 11% share of the total US oral mesalamine / olsalazine prescription market in September 2004 (September 2003: 11%).
A fourth drug in this class, olsalazine
, is not approved for induction but is sometimes used for maintenance.
1 IMS Prescription Data - ADHD market 2 IMS Prescription Data - extended release carbamazepine market 3 IMS Prescription Data - AGRYLIN, Hydrea, generic hydroxyurea market 4 IMS Prescription Data - mesalamine / olsalazine
market 5 IMS Prescription Data - PROAMATINE and fludrocortisone acetate market 6 IMS Prescription Data - Product specific 7 GSK OVERVIEW OF US GAAP FINANCIAL RESULTS Introduction
0% (5) (1) ADHD market (2) extended release carbamazepine market (3) AGRYLIN, Hydrea, generic hydroxyurea market (4) mesalamine / olsalazine
market (5) PROAMATINE and fludrocortisone acetate market (6) IMS Prescription Data CNS Franchise ADDERALL XR and ADDERALL
Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis.
Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study.
Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine.